Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

208 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Cardiovascular disease in immune-mediated inflammatory diseases: A cross-sectional analysis of 6 cohorts.
Fernández-Gutiérrez B, Perrotti PP, Gisbert JP, Domènech E, Fernández-Nebro A, Cañete JD, Ferrándiz C, Tornero J, García-Sánchez V, Panés J, Fonseca E, Blanco F, Rodríguez-Moreno J, Carreira P, Julià A, Marsal S, Rodriguez-Rodriguez L; IMID Consortium. Fernández-Gutiérrez B, et al. Medicine (Baltimore). 2017 Jun;96(26):e7308. doi: 10.1097/MD.0000000000007308. Medicine (Baltimore). 2017. PMID: 28658137 Free PMC article.
Evaluation of a shared autoimmune disease-associated polymorphism of TRAF6 in systemic sclerosis and giant cell arteritis.
Carmona FD, Serrano A, Rodríguez-Rodríguez L, Callejas JL, Simeón CP, Carreira P, Castañeda S, Solans R, Blanco R; Spanish Scleroderma Group; Spanish Giant Cell Arteritis Group; González-Gay MA, Martín J. Carmona FD, et al. J Rheumatol. 2012 Jun;39(6):1275-9. doi: 10.3899/jrheum.120038. Epub 2012 May 15. J Rheumatol. 2012. PMID: 22589256
Risk variants for psoriasis vulgaris in a large case-control collection and association with clinical subphenotypes.
Julià A, Tortosa R, Hernanz JM, Cañete JD, Fonseca E, Ferrándiz C, Unamuno P, Puig L, Fernández-Sueiro JL, Sanmartí R, Rodríguez J, Gratacós J, Dauden E, Sánchez-Carazo JL, López-Estebaranz JL, Moreno-Ramírez D, Queiró R, Montilla C, Torre-Alonso JC, Pérez-Venegas JJ, Vanaclocha F, Herrera E, Muñoz-Fernández S, González C, Roig D, Erra A, Acosta I, Fernández-Nebro A, Zarco P, Alonso A, López-Lasanta M, García-Montero A, Gelpí JL, Absher D, Marsal S. Julià A, et al. Hum Mol Genet. 2012 Oct 15;21(20):4549-57. doi: 10.1093/hmg/dds295. Epub 2012 Jul 19. Hum Mol Genet. 2012. PMID: 22814393
GWAS replication study confirms the association of PDE3A-SLCO1C1 with anti-TNF therapy response in rheumatoid arthritis.
Acosta-Colman I, Palau N, Tornero J, Fernández-Nebro A, Blanco F, González-Alvaro I, Cañete JD, Maymó J, Ballina J, Fernández-Gutiérrez B, Olivé A, Corominas H, Erra A, Canela-Xandri O, Alonso A, López Lasanta M, Tortosa R, Julià A, Marsal S. Acosta-Colman I, et al. Pharmacogenomics. 2013 May;14(7):727-34. doi: 10.2217/pgs.13.60. Pharmacogenomics. 2013. PMID: 23651021
Tocilizumab in patients with active rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs or tumor necrosis factor inhibitors: subanalysis of Spanish results of an open-label study close to clinical practice.
Álvaro-Gracia JM, Fernández-Nebro A, García-López A, Guzmán M, Blanco FJ, Navarro FJ, Bustabad S, Armendáriz Y, Román-Ivorra JA; ACT SURE. Álvaro-Gracia JM, et al. Reumatol Clin. 2014 Mar-Apr;10(2):94-100. doi: 10.1016/j.reuma.2013.07.002. Epub 2013 Oct 5. Reumatol Clin. 2014. PMID: 24099961 Free article. Clinical Trial. English, Spanish.
Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis.
Montes A, Perez-Pampin E, Narváez J, Cañete JD, Navarro-Sarabia F, Moreira V, Fernández-Nebro A, Del Carmen Ordóñez M, de la Serna AR, Magallares B, Vasilopoulos Y, Sarafidou T, Caliz R, Ferrer MA, Joven B, Carreira P, Gómez-Reino JJ, Gonzalez A. Montes A, et al. Pharmacogenet Genomics. 2014 May;24(5):238-45. doi: 10.1097/FPC.0000000000000042. Pharmacogenet Genomics. 2014. PMID: 24667440
Analysis of disease activity and response to treatment in a large Spanish cohort of patients with systemic lupus erythematosus.
Pego-Reigosa JM, Rúa-Figueroa Í, López-Longo FJ, Galindo-Izquierdo M, Calvo-Alén J, Olivé-Marqués A, del Campo V, García-Yébenes MJ, Loza-Santamaría E, Blanco R, Melero-González R, Vela-Casasempere P, Otón-Sánchez T, Tomero-Muriel E, Uriarte-Isacelaya E, Fito-Manteca MC, Freire-González M, Narváez J, Fernández-Nebro A, Zea-Mendoza A, Rosas J; RELESSER Group, from the Spanish Society of Rheumatology Systemic Autoimmune Diseases Study Group (EASSER). Pego-Reigosa JM, et al. Lupus. 2015 Jun;24(7):720-9. doi: 10.1177/0961203314563818. Epub 2014 Dec 15. Lupus. 2015. PMID: 25516473 Clinical Trial.
Comprehensive description of clinical characteristics of a large systemic lupus erythematosus cohort from the Spanish Rheumatology Society Lupus Registry (RELESSER) with emphasis on complete versus incomplete lupus differences.
Rúa-Figueroa Í, Richi P, López-Longo FJ, Galindo M, Calvo-Alén J, Olivé-Marqués A, Loza-Santamaría E, Vicente SP, Erausquin C, Tomero E, Horcada L, Uriarte E, Sánchez-Atrio A, Rosas J, Montilla C, Fernández-Nebro A, Rodríguez-Gómez M, Vela P, Blanco R, Freire M, Silva L, Díez-Álvarez E, Ibáñez-Barceló M, Zea A, Narváez J, Martínez-Taboada V, Marenco JL, de Castro MF, Fernández-Berrizbeitia O, Hernández-Beriain JÁ, Gantes M, Hernández-Cruz B, Pérez-Venegas JJ, Pecondón Á, Marras C, Carreira P, Bonilla G, Torrente V, Castellví I, Alegre J, Moreno M, Raya E, de la Peña PG, Vázquez T, Aguirre Á, Quevedo V, Pego-Reigosa JM; EAS-SER (Systemic Diseases Study Group of the Spanish Society of Rheumatology). Rúa-Figueroa Í, et al. Medicine (Baltimore). 2015 Jan;94(1):e267. doi: 10.1097/MD.0000000000000267. Medicine (Baltimore). 2015. PMID: 25569641 Free PMC article.
A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility.
Carmona FD, Mackie SL, Martín JE, Taylor JC, Vaglio A, Eyre S, Bossini-Castillo L, Castañeda S, Cid MC, Hernández-Rodríguez J, Prieto-González S, Solans R, Ramentol-Sintas M, González-Escribano MF, Ortiz-Fernández L, Morado IC, Narváez J, Miranda-Filloy JA; Spanish GCA Group; Beretta L, Lunardi C, Cimmino MA, Gianfreda D, Santilli D, Ramirez GA, Soriano A, Muratore F, Pazzola G, Addimanda O, Wijmenga C, Witte T, Schirmer JH, Moosig F, Schönau V, Franke A, Palm Ø, Molberg Ø, Diamantopoulos AP, Carette S, Cuthbertson D, Forbess LJ, Hoffman GS, Khalidi NA, Koening CL, Langford CA, McAlear CA, Moreland L, Monach PA, Pagnoux C, Seo P, Spiera R, Sreih AG, Warrington KJ, Ytterberg SR, Gregersen PK, Pease CT, Gough A, Green M, Hordon L, Jarrett S, Watts R, Levy S, Patel Y, Kamath S, Dasgupta B, Worthington J, Koeleman BP, de Bakker PI, Barrett JH, Salvarani C, Merkel PA, González-Gay MA, Morgan AW, Martín J. Carmona FD, et al. Am J Hum Genet. 2015 Apr 2;96(4):565-80. doi: 10.1016/j.ajhg.2015.02.009. Epub 2015 Mar 26. Am J Hum Genet. 2015. PMID: 25817017 Free PMC article.
FCGR polymorphisms in the treatment of rheumatoid arthritis with Fc-containing TNF inhibitors.
Montes A, Perez-Pampin E, Joven B, Carreira P, Fernández-Nebro A, Del Carmen Ordóñez M, Navarro-Sarabia F, Moreira V, Vasilopoulos Y, Sarafidou T, Caliz R, Ferrer MA, Cañete JD, de la Serna AR, Magallares B, Narváez J, Gómez-Reino JJ, Gonzalez A. Montes A, et al. Pharmacogenomics. 2015;16(4):333-45. doi: 10.2217/pgs.14.175. Pharmacogenomics. 2015. PMID: 25823782
208 results